News >

Successful ESMO Studies to Likely Trigger Sequencing Shakeup in RCC

Gina Columbus @ginacolumbusonc
Published: Thursday, Sep 28, 2017

Rana R. McKay, MD

Rana R. McKay, MD
On the heels of the pivotal CABOSUN and CheckMate-214 studies demonstrating the promise of cabozantinib (Cabometyx) and nivolumab (Opdivo)/ipilimumab (Yervoy) as frontline therapies for patients with metastatic renal cell carcinoma (mRCC), respectively, physicians are already considering how potential regulatory approvals of these therapies could impact sequencing in the field.

In intermediate- and poor-risk patients, the median overall survival (OS) was not reached in the nivolumab/ipilimumab arm and was 26.0 months with sunitinib, and progression-free survival (PFS) was 11.6 months and 8.4 months in the 2 arms, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication